BeOne Medicines News and Activities
Presence
BeOne Medicines develops and sells cancer medicines and related drug services. Its products and research programs serve hospitals, doctors, and patients, with a focus on oncology treatment in China and global markets.
BeOne Medicines products and services overview:
- Cancer medicines
- Drug research
- Biologic therapies
- Small molecule drugs
- Clinical development
- Commercial medicines
Revenue: ~$4 billion
Employees: 11,000
Headquarters: Beijing, China
BeOne Medicines is one of the...
BeOne Medicines is a company listed under the stock ticker 688235 (HK).
BeOne Medicines has a direct presence in 2 countries.
They are in:
- Biotechnology67%
- Pharmaceuticals33%
Acquisition, funding and merger involving BeOne Medicines.
- BeOne Medicines has just announced a $885 Million fundraising (posted on August 28 2025).
- BeiGene will change its company name to BeOne Medicines. (posted on November 15 2024).
Executives
View the org chart displaying its 65 main executives
Most searched biographies at BeOne Medicines
- John Oyler, Chairman and Chief Executive Officer
- Michael Nuoqing Yi, Director
- Corsee Sanders, Director
Create your alert
to follow the executive moves at BeOne Medicines.
Pharmaceuticals
BeOne Medicines has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by BeOne Medicines
- BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe – NASDAQ (US) Website
- TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy – NASDAQ (US) Website
- BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference – NASDAQ (US) Website
- BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets – NASDAQ (US) Website
- BeiGene Unveils Breast Cancer Pipeline – NASDAQ (US) Website
- BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor – NASDAQ (US) Website
- BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 – NASDAQ (US) Website
- BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL – NASDAQ (US) Website
- European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer – NASDAQ (US) Website
- Press Releases – NASDAQ (US) Website
- View more press releases Close
Social media about BeOne Medicines
- BeOne Medicines on Wikipedia, Google News & Yahoo Finance
- BeOne Medicines on LinkedIn, X (Twitter) & YouTube
